| Literature DB >> 36141702 |
Bing Li1, Weicong Xu2,3, Ruxin Luo4, Shaojie Zhuo4, Xueyan Guo4, Kuan Cheng4, Keming Yun1, Dong Ma4.
Abstract
Arsenic (As) and its compounds are widely used in many applications. Long-term exposure to As can cause acute and chronic poisoning. In severe cases, it can lead to adverse effects, such as gene mutation, cell cancer and fetal malformation. The objective of this study was to accurately estimate As exposure frequency and time. Quantitative analysis of As in single hairs obtained from APL (acute promyelocytic leukemia) patients treated with As2O3 was performed by LA-ICP-MS. An informative As concentration distribution profile of single hair was applied to estimate the As exposure frequency and time. As exposure frequency was estimated according to the number of As concentration peaks. As exposure time was estimated according to the hair growth length in combination with the hair growth rate. The validation results demonstrate that this method was more efficient than the traditional method; compared with the traditional method, which provides estimates in months, our model shortened the As exposure time estimate to the range of a few days, which considerably improved the inference accuracy. Therefore, these results can be used for forensic toxicology studies, environmental exposure monitoring, etc.Entities:
Keywords: LA-ICP-MS; arsenic; exposure time; frequency; hair growth rate; single hair
Mesh:
Substances:
Year: 2022 PMID: 36141702 PMCID: PMC9517363 DOI: 10.3390/ijerph191811429
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Detailed medical profiles of all patients.
| Patient | 1st Course | 2nd Course | 3rd Course | 4th Course | 5th Course | 6th–10th Course | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AT (Day) | WT (Day) | AT (Day) | WT (Day) | AT (Day) | WT (Day) | AT (Day) | WT (Day) | AT (Day) | WT (Day) | AT (Day) | WT (Day) | |
| 1 | 22 | 18 | 14 | 16 | 14 | 15 | 14 | 18 | 14 | - | - | - |
| 2 | 14 | 15 | 14 | 45 | 14 | 18 | 14 | - | - | - | - | - |
| 3 | 14 | 58 | 14 | 17 | 14 | 58 | 14 | - | - | - | - | - |
| 4 | 14 | 57 | 14 | 18 | 14 | 19 | - | - | - | - | - | - |
| 5 a | 14 | 18 | 14 | 15 | 14 | 18 | 14 | 67 | 14 | - | 14 | - |
| 6 | 14 | 17 | 14 | - | - | - | - | - | - | - | - | - |
| 7 | 14 | 21 | 14 | 21 | 14 | 51 | 14 | 17 | 14 | - | - | - |
| 8 b | 10 | 7 | 14 | 17 | 14 | 31 | 14 | 17 | 14 | - | - | - |
| 11 | 15 | - | - | |||||||||
AT, administration time; WT, withdraw time. a Patient No. 5 received a 10-course As2O3 treatment comprising an oral dose of 10 mg As2O3 for 14 continuous days for each course; the interval for the 6th to 10th courses ranged from 13 days to 50 days. b Cessation of As2O3 administration occurred during the first course for patient No. 8; therefore, the first course was divided into two stages.
Figure 1Arsenic concentration profiles of five hairs collected from the occipital region of patient No. 1. H-1 to H-5 represented hair samples 1 to 5, respectively.
Figure 2Arsenic exposure frequency for patient No. 1.
Hair growth rate measured by arsenic longitudinal distribution along hair strands.
| Patient No. | Sex | Age | Hair Growth Rate: | Intraindividual CV (%) | Interindividual CV (%) | |
|---|---|---|---|---|---|---|
| 1 | F | 25 | 439 ± 15 (406,471) | 3.39 | 6.37 | |
| 2 | F | 28 | 424 ± 23 (370,477) | 5.48 | 2.82 | |
| 3 | M | 35 | 403 ± 24 (348,459) | 5.94 | −2.18 | |
| 4 | F | 30 | 418 ± 29 (343,493) | 6.99 | 1.45 | |
| 5 | F | 46 | 398 ± 12 (374,423) | 2.94 | −3.36 | |
| Mean | 412 ± 8 | 1.93 | 1.02 | |||
M, male; F, female; y, years; SD, standard deviation; CV, coefficient of variation.
Figure 3Arsenic concentration profiles for patient No. 8, A-F represents the interval between adjacent sessions.
Estimation results for patient No. 8.
| Hair Length (cm) | Actual | Estimated | Accuracy (%) | Time of Deviation (day) | |
|---|---|---|---|---|---|
| A | 0.78 | 17 | 18.89 | 111.09 | 1.89 |
| B | 1.04 | 26 | 25.24 | 97.08 | −0.76 |
| C | 1.35 | 31 | 32.77 | 105.71 | 1.77 |
| D | 1.49 | 45 | 36.17 | 80.38 | −8.83 |
| E | 1.20 | 31 | 29.13 | 93.97 | −1.87 |
| F | 0.71 | 20 | 17.24 | 86.20 | −2.76 |
| A→F | 6.57 | 170 | 159.89 | 89.04 | −10.53 |
Estimation results of continuous days of As2O3 administration in each course for patient No. 8.
| Course | Hair | Actual | Estimated | Accuracy | Time of Deviation (Day) | |
|---|---|---|---|---|---|---|
| 1 | Stage 1 | 0.45 | 10 | 10.92 | 109.20 | 0.92 |
| Stage 2 | 0.46 | 11 | 11.17 | 101.55 | 0.17 | |
| 2 | 0.60 | 14 | 14.56 | 104.00 | 0.56 | |
| 3 | 0.53 | 14 | 12.87 | 91.93 | −1.13 | |
| 4 | 0.55 | 14 | 13.35 | 95.36 | −0.65 | |
| 5 | 0.61 | 14 | 14.81 | 105.79 | 0.81 | |
Figure 4Concentration along hair from a victim of arsenic poisoning.